---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-307926"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:37:56.654993+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Mirum Pharmaceuticals director Carol Brosgart resigns, becomes senior advisor; Lon Cardon appointed to board

## Summary
- Carol L. Brosgart resigned as director and Nominating Committee member effective Dec 19, 2022; no dispute; becomes senior advisor in science and policy.
- Lon Cardon, Ph.D., appointed to board as Class I director, term expiring at 2023 annual meeting, and to Nominating and Corporate Governance Committee.
- Cardon receives option for 34,000 shares vesting in 3 equal annual installments, plus annual cash retainer of $40,000 ($4,000 for committee service) prorated for 2022.
- Cardon eligible for annual option grant of 17,000 shares starting at 2023 annual meeting, prorated per policy.
- Standard indemnification agreement entered; no arrangements with other persons for selection.

## SEC filing metadata
- accession: 0001193125-22-307926
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/0001193125-22-307926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/d436545d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-307926
- JSON: https://secwatch.observer/filing/0001193125-22-307926.json
- Plain text: https://secwatch.observer/filing/0001193125-22-307926.txt

## Key facts
- Executive change
  Carol L. Brosgart resigned as Director at Mirum Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On December 16, 2022, Carol L. Brosgart, M.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective December 19, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/0001193125-22-307926-index.htm
- Executive change
  Lon Cardon was appointed as Director at Mirum Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 19, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lon Cardon, Ph.D., FMedSci, to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/0001193125-22-307926-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.